Site icon MSN Technology

Trump admin picks COVID critic to be top FDA vaccine regulator

GettyImages 628879332 2560x1440

GettyImages 628879332

A discriminatory critic of the Kovide 19 reaction, will be the next regulator of the vaccine in the Food and Drug Administration, Food and Drug Administration, Agency Commissioner Martin Makri. Announced on social media on Tuesday.

The Prasad will be headed by the FDA’s Center for Bocoology Evolution and Research (CBER), which is in charge of approval and management of vaccine and other biology products, such as gene therapy and blood products.

“The scientific hardship, freedom, and transparency that Dr. Prasad needs in the CBER,” McCari wrote on social media. This is an important step ahead. “

Professor Prasad from the University of California, San Francisco’s Department of Epidemology and Biostics, is probably known for his social media posting and criticism of the mainstream medical community. It gained notoriety between the Covid 19 pandemic diseases to attack the masked and vaccine mandate, such as masked and vaccine mandate.

In a newsletter of October 2021, which is titled “How does democracy end“Prasad compared the country’s pandemic response to the rise of Adolf Hitler’s third Reich. Under the leadership of this post, New York University’s biothekest Arthur Caplin compared Prasad, writing in a cancer letter,” comparison. “Ridiculous, dangerous and invasive“” Imbecilic “before adding.

Prasad has also criticized the FDA for approval of the Kovide 19 booster vaccines. Last year, he accused his predecessor of being the head of the CBER, Peter Marx.Either incompetent or abusive“To allow approval.

“Believed”

Recently, Prasad has praised the new FDA Commissioner Macri, while criticizing the marks. At the beginning of March, Prasad said Macri “Careful, thinking, and discipline” and “exactly what we need in the FDA.” At the end of the month, he wrote taking shots on Marx: “You can convert Peter Marks from Bubble Head Doll It only seals approval and you will have the same result with low administrative fees in the FDA. It may be that something should be considered. “

Source link

Exit mobile version